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A B S T R A C T
Background: The cytokine growth diﬀerentiation factor-15 (GDF-15) has been associated with inﬂammatory and
mitochondrial disease, warranting exploration of its expression in myositis patients.
Methods: GDF-15 protein levels are evaluated in 35 idiopathic inﬂammatory myopathy (IIM) serum samples
using enzyme-linked immunosorbent assays, comparing with levels in samples from healthy individuals and
from patients with genetically conﬁrmed hereditary muscular dystrophies and mitochondrial disorders. Muscle
tissue expression of GDF-15 protein is evaluated using immunoﬂuorescent staining and Western blotting.
Results: GDF-15 protein levels are signiﬁcantly higher in IIM sera (625 ± 358 pg/ml) than in that of healthy
controls (326 ± 204 pg/ml, p = 0.01). Western blotting conﬁrms increased GDF-15 protein levels in IIM
muscle. In skeletal muscle tissue of IIM patients, GDF-15 localizes mostly to small regenerating or denervated
muscle ﬁbres. In patients diagnosed with sporadic inclusion body myositis, GDF-15 co-localizes with the char-
acteristic protein aggregates within aﬀected muscle ﬁbres.
Conclusions: We describe for the ﬁrst time that GDF-15 is a myokine upregulated in myositis and present the
cytokine as a potential diagnostic serum biomarker.
1. Introduction
Idiopathic inﬂammatory myopathies (IIM) also termed myositis are
a heterogeneous group of rare muscle diseases subtyped based upon
clinical characteristics and their associated skeletal muscle damages.
Dermatomyositis (DM) patients develop complement-mediated blood
vessel destruction, perimysial inﬂammation and perifascicular muscle
ﬁbre atrophy, and often display typical cutaneous manifestations.
Polymyositis (PM) and sporadic inclusion body myositis (IBM) are
characterized by invasion of nonnecrotic muscle ﬁbres by auto-ag-
gressive cytotoxic T-cells and macrophages, with inﬂammation building
up mostly at endomysial sites. IBM muscle ﬁbres additionally develop
degenerative changes, with rimmed vacuoles and inclusions containing
aggregates of ectopic proteins. In immune-mediated necrotizing myo-
pathy (IMNM), necrosis of muscle ﬁbres predominates over tissue in-
ﬂammation. Additional subtypes based upon associated autoantibody
proﬁles have recently been recognized, and subgroups of patients de-
velop overlap myositis associated with other rheumatic diseases [1].
Biomarker development aimed at discriminating IIM from other muscle
diseases and subtyping disease groups, remains a priority for these
pathologies.
An altered mitochondrial phenotype has long been recognized in the
subgroup of IBM patients, largely based upon the histological evidence
of ragged-red ﬁbres and cytochrome c oxidase deﬁcient muscle ﬁbres in
patient biopsies [2]. In addition, hereditary muscular dystrophies may
contain mitochondrial abnormalities [3], and prominent mitochondrial
damage is observed in individuals with PM poorly responsive to im-
munosuppressive therapy, a disorder also termed PM with mitochon-
drial pathology [4]. As growth diﬀerentiation factor-15 (GDF-15) is
involved in both mitochondrial [5] and inﬂammatory [6] regulation,
we set out to investigate this cytokine in the IIM. GDF-15 is a member of
the transforming growth factor-β (TGF-β) superfamily of cytokines with
many aliases, and is also called prostate diﬀerentiation factor, macro-
phage inhibitory cytokine-1, placental bone morphogenetic protein,
non-steroidal inﬂammatory drug-activated protein 1, and placental
TGF-β. It is a versatile regulatory factor that behaves as a transcription
factor in the cell’s nucleus, and in the cytoplasm associates with mi-
tochondria regulating the cell’s energy homeostasis [7]. The secreted
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disulﬁde bond-linked GDF-15 dimer possesses endocrine functions,
controlling food intake and body weight [8].
2. Patients and methods
2.1. Patients
This retrospective study includes muscle biopsies and sera from an
established cohort of 35 IIM patients clinically and myopathologically
diagnosed with IMNM (n = 21), IBM (n = 10), PM (n = 3), and DM
(n = 1) (Supplementary Table 1). Controls are ten commercial sera
from healthy subjects aged between 22 and 41 years (Zenbio, Durham,
NC) and sera from patients with hereditary muscle disease: Patients
with limb girdle muscular dystrophy due to homozygous c.191dupA in
the ANO5 gene and c.1A > G in the BVES gene, and a patient with
clinical IBM carrying a homozygous c.374G > A alteration in VCP. As
positive controls, ﬁve patients with mitochondrial myopathy are in-
cluded, in which disease is due to heteroplasmic m.3243A > G mu-
tations leading either to chronic progressive external ophtalmoplegia,
or mitochondrial encephalopathy, lactic acidosis, and stroke-like epi-
sodes; a homoplasmic m.11778G > A mutation causing Leber's her-
editary optic neuropathy; and a nuclear POLG variant c.2864A > G
(p.Tyr955Cys) causing chronic progressive external ophtalmoplegia.
2.2. Enzyme-linked immunosorbent assays
Enzyme-linked immunosorbent assays are performed with the
Human GDF-15 DuoSet ELISA kit from R&D Systems (Bio-Techne,
Abingdon, UK) according to the manufacturer’s speciﬁcations.
Duplicates of sera diluted 1/10 and 1/20 (controls), 1/10 and 1/50
(patients), are loaded onto 96-well plates. Values are calculated as the
mean of duplicates and of the two dilutions tested, and reported as
mean ± SD. Shapiro-Wilk test ruled out normality of result values,
hence the Mann-Whitney U test is used to investigate signiﬁcance.
Wilcoxon Signed Rank test is used to analyse a possible association of
GDF-15 levels with clinical characteristics. All analyses are done with
SPSS software version 25 (IBM, New York, NY).
2.3. Immunoﬂuorescent staining
To visualize GDF-15 in frozen muscle sections, 4 µg/ml mouse
monoclonal IgG2a (clone H-2, Santa Cruz Biotechnology, Santa Cruz,
CA) and 10 µg/ml goat polyclonal (B2413, LifeSpan BioSciences,
Seattle, WA) anti-GDF-15 antibodies are used. Blocking and incubations
with primary antibodies are carried out in phosphate buﬀered saline
with 5% donkey serum, 10% heat-inactivated human serum and 2%
bovine serum albumin (Millipore Sigma, St Louis, MO). Double staining
is done with 0.7 µg/ml rabbit polyclonal anti-CD68 (H-255, Agilent,
Santa Clara, CA), 1 µg/ml rabbit polyclonal anti-CD56 (Fisher
Scientiﬁc, Waltham, MA), 1.3 µg/ml mouse monoclonal IgG1 anti-p62
(BD Biosciences, San Jose, CA), 1.25 µg/ml rabbit polyclonal anti-LC3B
(Abcam, Cambridge, UK), and 28.5 µg/ml rabbit anti-von Willebrand
factor (Agilent). Fluorescent secondary antibodies are used labelled
with CY3 (Jackson ImmunoResearch Laboratories, West Grove, PA) and
AlexaFluor488 (Invitrogen, Carlsbad, CA). Slides are mounted with
Fluoromount (Southern Biotech, Birmingham, AL) and analysed under
a ﬂuorescence microscope (Zeiss, Goettingen, Germany). Controls
consist of the omission of primary antibody and the substitution by non-
immune IgGs.
2.4. Western blotting
Protein samples are prepared from muscle biopsies using a com-
mercial extraction kit (Fisher Scientiﬁc). Proteins are separated on a
10% bis tris polyacrylamide gel and blotted onto a nitrocellulose
membrane (Invitrogen). The membrane is incubated overnight with
0.2 µg/ml rabbit polyclonal anti-glyceraldehyde 3-phosphate dehy-
drogenase, tris-buﬀered saline with 2% milk added served as blocking
and incubation solution. Chemiluminescence is generated after in-
cubating 1 h with 1 µg/ml peroxidase-labelled goat anti-rabbit by
adding the Clarity Max substrate (Biorad, Hercules, CA), visualized with
the Chemidoc Imaging System and Image Lab 6.0 software (Biorad).
The same membrane is then washed and incubated with 2 µg/ml mouse
monoclonal IgG2a anti-GDF-15 (clone H-2, SantaCruz Biotechnology)
for 4 h at room temperature, followed by colorimetric visualization
using the WesternBreeze anti-mouse kit (Invitrogen).
3. Results
Serum levels of GDF-15 are increased in IIM patients (Fig. 1).
Compared to controls (326 ± 204 pg/ml), circulating GDF-15 levels
are signiﬁcantly higher in IIM patients (625 ± 358 pg/ml) according
to the Mann-Whitney U test (p = 0.01), with levels not signiﬁcantly
diﬀerent between IMNM (557 ± 368 pg/ml) and IBM
(747 ± 326 pg/ml) subgroups (p = 0.1). GDF-15 levels do not cor-
relate with CK values (p = 0.2), gender (p = 0.07), associated other
autoimmune diseases (p = 0.3), autoantibody positivity (p = 0.9),
malignancy (p = 0.5), or extensive endomysial inﬂammation
(p = 0.07). GDF-15 levels in patients diagnosed with limb girdle
muscular dystrophy and hereditary IBM (127 ± 41 pg/ml) are notably
Fig. 1. Graphic representation of circulating
growth diﬀerentiation factor-15 (GDF-15) ex-
pressed as pg per ml serum. Mean levels in
healthy controls (CONT), patients diagnosed
with idiopathic inﬂammatory myopathies (IIM),
hereditary muscular dystrophies (HERM), and
mitochondrial myopathy (MITM) are shown.
Mean ages of subjects ± SD and the numbers of
patients per group were: 33.7 ± 12.1n = 10
(CONT), 63.7 ± 10.5n = 35 (IIM),
43.0 ± 15.4n = 3 (HERM) and 40.8 ± 16.2
n = 5 (MITM).
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lower. Sera from patients with mitochondrial disease display highest
mean values (1312 ± 1393 pg/ml) and largest variations between
individual samples, as has been reported [5].
Only low constitutive GDF-15 staining is present in healthy skeletal
muscle, with rare muscle ﬁbres displaying low sarcoplasmic expression
and discontinuous staining along the muscle ﬁbre edges. Staining in-
creases in IIM muscle, with the sarcoplasm of small ﬁbres often positive,
most of which are CD56 positive regenerating or denervated muscle
ﬁbres (Fig. 2J–L). In IBM samples, subsets of ﬁbres contain strong
granular GDF-15 staining, which co-localizes with the autophagic
markers p62/Sequestosome-1 (Fig. 2A–C) and LC3B (Fig. 2D–F). The
vast majority of inﬂammatory cells are negative, with only occasional
CD56 positive activated cytotoxic muscle ﬁbre-invading cells staining
positive (Fig. 2G–I), representing natural killer cells, cytotoxic T-cells,
or M1 type macrophages [9]. Immunostaining patterns are similar for
both antibodies used. Western blotting conﬁrms GDF-15 expression in
IIM muscle, with expression levels in control samples being below the
detection limit (Fig. 2).
4. Discussion
Growth factors and cytokines are key factors in the pathogenesis of
Fig. 2. Expression of growth diﬀerentiation
factor-15 (GDF-15) in skeletal muscle tis-
sues. Immunoﬂuorescence panel.
Sporadic inclusion body myositis. A: Strong
granular staining for GDF-15 (CY3, red) is
observed in a muscle ﬁbre, B: Staining for
the autophagic marker p62 (AlexaFluor488,
green) shows the inclusions present in the
muscle ﬁbre. C: Presence of GDF-15 in the
inclusions is shown in the combination
image. D: A muscle ﬁbre is strongly positive
for GDF-15 (CY3, red). E: The muscle ﬁbre is
also positive for autophagic marker LC3B
(AlexaFluor488, green). F: A double ﬂuor-
escence combination image is shown.
Immune-mediated necrotizing myopathy. G:
A single cell stains for GDF-15 (CY3, red). H:
Staining for CD56 (AlexaFluor488, green)
identiﬁes activated immune cells. I: The
combination image shows the single GDF-15
positive immune cell invading a necrotic
muscle ﬁbre (arrow in all three images).
Polymyositis. J: Muscle ﬁbres stain for GDF-
15 (CY3, red) in the sarcoplasm and on the
ﬁbre’s edges. K: Staining with CD56
(AlexaFluor488, green) identiﬁes re-
generating or denervated muscle ﬁbres. L:
Double ﬂuorescence combination image.
Scale bar = 50 µm. Western blotting
panel. A protein band for GDF-15 can only
be detected in muscle samples from patients
diagnosed with dermatomyositis (DM) and
sporadic inclusion body myositis (IBM),
while the protein could not be detected in
ﬁve healthy control samples (C). Protein
bands of the housekeeping protein glycer-
aldehyde 3-phosphate dehydrogenase
(GAPDH) detected on the same membrane
are given to evaluate equal loading.
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the IIM [10] and in this light serum levels have been proposed as a
means to monitor disease activity in DM. For GDF-15, it has been es-
tablished that systemic levels vary in response to activity and stress,
elevating after exercise [11] and in response to disease and organ injury
[12]. Most notable increases have been observed in mitochondrial
myopathy [5]. We now report for the ﬁrst time a signiﬁcant increase of
GDF-15 levels in serum of IIM patients, with muscle representing a
probable source. GDF-15 levels are increased in CD56 positive muscle
ﬁbres undergoing active regeneration or denervation, processes that are
frequent in IIM muscle. We put forward circulating GDF-15 levels as a
convenient potential biomarker to identify IIM patients. Although mi-
tochondrial dysfunction is generally considered more pronounced in
IBM compared to IMNM, GDF-15 serum levels were not signiﬁcantly
diﬀerent between the two patient subgroups. Our observations would,
however, need to be conﬁrmed in larger patient cohorts. IIM are rare
diseases, and existing international collaborations [13] can make it
possible to further test the diagnostic potential of GDF-15 in the future.
Also, our control group’s average age was lower than that of IIM pa-
tients (33.7 versus 63.7 years of age), which could require checking in
an aged-matched control group in the future to fully rule out an age
eﬀect.
Sub-classiﬁcation of the diﬀerent IIM groups remains highly re-
levant for guiding therapeutic decisions and for oﬀering founded
prognoses. In this respect, autoantibody proﬁling is a recent addition to
the diagnostic arsenal which already proved to be of primordial im-
portance [14]. In addition to its powers for disease subtyping, ser-
otyping oﬀers also important indicators to aid patient follow-up. The
presence of anti-MDA5 autoantibodies for instance, associates with
severe interstitial lung disease, while anti-NXP-2 and anti-TIF-1γ on the
other hand associate with malignancy. Analysing serum parameters has
therefore ﬁrmly gained its place in the diagnostic workup of IIM, with
blood samples being a convenient, low-invasive and expanding source
of diagnostic information. Accurate and early subtyping of IBM is also
very important for prognosis and guiding therapy, as in most instances
this disease subtype is irresponsive to immunosuppressive therapies.
Histological markers of IBM are available today, and concern compo-
nents of the cytoplasmic inclusions that are present in muscle ﬁbers,
namely TAR DNA-binding protein 43 (TDP-43) and p62/Sequestosome-
1 [15]. It has been recommended to combine markers to reach both
high sensitivity and speciﬁcity, and we now propose GDF-15 as an
additional aggregate-associated factor with biomarker potential.
5. Conclusions
We propose GDF-15 testing as possible addition to the diagnostic
workup of IIM, with potential to reduce the diagnostic delay and to
advance clinical care for this rare yet heterogeneous group of muscle
disorders.
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